GSK plc (GSK, GSK.L) has announced that Japan's Ministry of Health, Labour and Welfare has approved the extension of the indication for its RSV vaccine, Arexvy. This now includes adults aged 50-59 who are at an increased risk of respiratory syncytial virus (RSV) disease. Prior to this, since September 2023, the vaccine had been approved in Japan for adults aged 60 and over. This regulatory expansion is backed by data from a global Phase III clinical trial.
The company also highlighted that 35 countries, including the United States, have broadened approval for the use of its RSV vaccine in higher-risk populations.
